Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
about
Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances.Resources for Interpreting Variants in Precision Genomic Oncology Applications.Comprehensive Analysis of Hypermutation in Human Cancer.ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Actionable mutations in canine hemangiosarcoma.Hitting the Target: How T Cells Detect and Eliminate Tumors.Implementation of "Clinical Sequencing" in Cancer Genome Medicine in Japan.Immunotherapy for brain tumors: understanding early successes and limitations.Pancreatic cancer: Next-generation algorithms for neoantigen selection.Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.Environmental effects of ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2017.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology.Shed Skin Cancer, Not Collagen XVII: A New Approach to Targeting Skin Cancer Progression.Gene aberration profile of tumors of adolescent and young adult females.Blood- and tissue-based tumor genomics: a battle royale or match made in heaven?Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Salivary gland cancer patient-derived xenografts enable characterization of cancer stem cells and new gene fusions associated with tumor progression.Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Frameshift events predict anti-PD-1/L1 response in head and neck cancer.Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways.Precision Medicine in Head and Neck Cancer: Myth or Reality?Perspectives on the clinical development of immunotherapy in prostate cancer.A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report.
P2860
Q38599122-37FD0B18-767B-41BD-A096-CAFEC5542F9CQ38611235-CC91967D-3B25-4C8D-8AC6-E5E5E7E15EF8Q42353279-DD29A56E-B736-4F19-9079-4001084775C2Q42363061-A837ADDA-F456-44BF-9294-5D9106788E96Q46592106-396033A2-F3AF-40CC-BA08-BBA2B47CFDABQ46603813-71BDA4CE-789E-4369-8E02-1E8DEC1FEF5CQ47120629-68AB739B-9DC2-4795-AEF1-1C331DA8A759Q47133172-27783439-E0C6-4962-9A06-88D461E13F4DQ47153925-79CD4B3D-E161-42F2-B77E-732AD032464BQ47162757-28CF1ACD-3DFB-4606-B614-B27A739DCAE1Q47222791-B0EA0318-968B-4D01-AEA9-1D3D1B6B174AQ47235804-F19525C9-E294-4568-81F1-1687B86BB259Q47555498-907779B3-92C6-4582-9836-96798EE2CDC3Q47566281-9EA8AC37-5EDF-4049-9032-36E25138B5BFQ47800676-D16CC2E5-7D9B-447D-B107-DF234078CCF5Q47926486-1CD935AF-87AE-4B3A-A912-4791D18D8703Q48101797-70E8F57F-3382-4E03-A9ED-F73AE4C4C407Q48156858-9CFD8E29-1EF2-419C-ADD8-A79067544F63Q48168816-FC841117-0EE3-4785-ACDE-AB4F35ED7910Q48185876-5D30324B-A8D9-4915-934F-70BCEB6BF3FBQ48234912-43F9C5C2-ADEC-4CA1-85A6-8D7F89596741Q48316037-FA406EF2-0CC1-40C9-A2E2-AD295D7B4CDDQ49715015-7ADB693B-D7D6-48AA-A8D0-40FBE728C6CDQ49787556-BD3EDC60-E626-445E-8E30-233397A7097DQ49842940-96BE6957-F734-49A2-B4B2-67949BCE09D9Q49994174-8DCB2DA9-6CC7-4FAF-B8F7-C1F3D3468953Q50001757-91578920-2C32-4ECA-8DE8-5DDBA4BC332FQ50027697-D76493A7-E5AB-4674-AE02-B93C3DD52E54Q50049563-1E630686-A1AF-44D5-B7DB-4EC269DED045Q52385841-5EEB511D-E2E9-4F8C-852C-AB57B1B10B84Q52587406-7F91AFE3-B3E9-4545-88FC-8AC72FE3B1FCQ52648065-45EA7325-56F7-4253-B37D-B1069A98A540Q52655439-27C0ACD3-CB2D-4FB5-A46B-A201B05C65DBQ52721217-22374CF5-B222-4AC3-AA73-C4A78F3A6D42Q53695267-15D3AD48-5B4D-43BB-8507-50BE79B77043Q54269200-38E998E5-0386-4169-B8DC-A060EC59DAAAQ54976847-B09BCF2E-8ACA-4647-8439-BFF7DCB58225Q55012383-7DA9590C-ACF5-463C-90F2-720E2984ABF5Q55029444-FF6DA323-C26C-4562-9268-85D9175C7AE9Q55092262-B9FF455C-69ED-4923-97C9-69AA9F9E1AC8
P2860
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@ast
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@en
Analysis of 100,000 human canc ...... pe of tumor mutational burden.
@nl
type
label
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@ast
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@en
Analysis of 100,000 human canc ...... pe of tumor mutational burden.
@nl
prefLabel
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@ast
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@en
Analysis of 100,000 human canc ...... pe of tumor mutational burden.
@nl
P2093
P2860
P50
P1433
P1476
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
@en
P2093
Adam Shlien
Alexa Schrock
Brittany Campbell
Caitlin F Connelly
Daniel S Lieber
David Fabrizio
Franklin Huang
Garrett M Frampton
Geoffrey A Otto
P2860
P2888
P356
10.1186/S13073-017-0424-2
P577
2017-04-19T00:00:00Z
P6179
1084826380